Tuberculosis Clinical Trial
— PaSEMOfficial title:
An Open-Label Phase 2 Trial to Evaluate the Male Reproductive Safety of a 6-Month Combination Treatment for Pulmonary Tuberculosis (TB) of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) in Adult Male Participants With Drug Resistant Pulmonary TB
Verified date | September 2023 |
Source | Global Alliance for TB Drug Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pretomanid is being used in an antimicrobial combination regimen(s) to treat patients with pulmonary tuberculosis (TB). The primary purpose of the Male Reproductive Safety - "BPaMZ/SEM"- clinical study is to evaluate the potential effect of pretomanid on human testicular function whilst being used in a 26 weeks antimicrobial combination regimen consisting of bedaquiline (B) plus pretomanid (Pa) plus moxifloxacin (M) and pyrazinamide (Z) (BPaMZ).
Status | Active, not recruiting |
Enrollment | 26 |
Est. completion date | August 30, 2024 |
Est. primary completion date | June 19, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures. 2. Male gender 18 years or over 3. Body weight (in light clothing and no shoes) = 45kg. 4. A positive molecular test for tuberculosis in sputum either at screening or within one month prior to enrolment. 5. Disease Characteristics: - Participants must have been diagnosed with TB prior to or at screening - Participants' TB should be resistant to rifampicin and/or isoniazid, and susceptible to fluoroquinolones by rapid sputum-based tests. - Participants who have had previous treatment for DR-TB for more than 3 months at start of screening should be discussed with the medical monitor. 6. A chest x-ray, within 26 weeks prior to or at the screening visit, which in the opinion of the Investigator is compatible with pulmonary TB Exclusion criteria: 1. Resistant to fluoroquinolones by rapid molecular test 2. History of male infertility or vasectomy 3. Unable to produce semen sample 4. Evidence at screening of azoospermia 5. Known erectile dysfunction that would prevent ejaculation. 6. Historical or active disease process of the male reproductive tract that would compromise sperm production. e.g. tuberculous epididymitis. 7. History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. 8. For HIV infected participants any of the following: 1. CD4+ count <100 cells/µL 2. Received intravenous antifungal medication within the last 90 days 9. Participants with newly diagnosed tuberculosis and HIV that require initiation of appropriate HIV therapy before participants has received at least 2 weeks of an antituberculosis regimen. 10. Received pretomanid and/or delamanid to treat TB 11. Known chronic hepatitis B or C 12. For HIV infected participants: 1. The following antiretroviral therapy (ART) should not be used: 1. Stavudine 2. Zidovudine 3. Didanosine 4. Triple NRTI regimen is not considered optimal for HIV treatment (poor efficacy) 13. Participants with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (Draft November 2007) where applicable: 1. Platelets <75,000/mm3 2. Creatinine >1.5 times upper limit of normal (ULN) 3. eGFR = 60 mL/min 4. Haemoglobin <8.0 g/dL 5. Serum potassium less than the lower limit of normal for the laboratory. This may be repeated once 6. AST: - =3.0 x ULN to be excluded - results between 1.5 x ULN and 3 x ULN must be discussed with and approved by the Sponsor Medical Monitor 7. ALT: - =3.0 x ULN to be excluded - greater than ULN must be discussed with and approved by the Sponsor Medical Monitor 8. ALP: - =3.0 x ULN to be excluded - 2.0 - <3.0 x ULN must be discussed with and approved by the Sponsor Medical Monitor 9. Total bilirubin: - >1.5 x ULN to be excluded - Greater than ULN must be discussed with and approved by the Sponsor Medical Monitor 10. Direct bilirubin: • greater than 1x ULN to be excluded 11. Positive hepatitis B surface Ag, or hepatitis C antibody |
Country | Name | City | State |
---|---|---|---|
Georgia | National Center for Tuberculosis and Lung Diseases | Tbilisi | |
South Africa | CHRU, Sizwe Tropical Diseases Hospital | Johannesburg | |
South Africa | Isango Lethemba TB Research Unit Empilweni TB Hospital | Port Elizabeth | |
South Africa | The Aurum Institute: Rustenburg Clinical Research Centre | Rustenburg |
Lead Sponsor | Collaborator |
---|---|
Global Alliance for TB Drug Development |
Georgia, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Sperm Number - Week 26 | Change from baseline in total sperm number at 26 weeks of therapy. | Week 26 | |
Secondary | Total Sperm Number - Week 13 and Week 44 | Change from baseline in total sperm number at 13 weeks of therapy and at 18 weeks post end of therapy. | Week 13 to Week 44 | |
Secondary | Change in Male Reproductive Hormones | The change from baseline in Male reproductive hormones at Week 2, 4, 8, 12, 16, 35, 44, 52, 65, 78 and at early withdrawal. Reproductive hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), Inhibin B and Testosterone. | Up to Week 78 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |